𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Development of a sustained-release system for perivascular delivery of dipyridamole

✍ Scribed by Weiwei Zhu; Takahisa Masaki; You Han Bae; Ramesh Rathi; Alfred K. Cheung; Steven E. Kern


Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
197 KB
Volume
77B
Category
Article
ISSN
1552-4973

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Vascular access grafts implanted in dialysis patients are prone to failure in the long‐term because of stenosis and occlusion caused by neointimal hyperplasia. Local delivery of antiproliferative drugs may be effective to prevent this consequence while minimizing the systemic side effects they cause. We developed a combination of poly(lactide‐co‐glycolide) (PLGA) microspheres with ReGel®, an injectable copolymer, as a sustained‐release system for perivascular delivery of an antiproliferative drug, dipyridamole. Dipyridamole‐incorporated PLGA microspheres with various molecular weights (MWs) of PLGA were prepared by oil‐in‐water emulsion method. Encapsulation efficiency and surface morphology of microspheres were characterized. In vitro release kinetics of dipyridamole from ReGel or from microspheres/ReGel was experimentally determined. Without microspheres, 40% of the dipyridamole was released from ReGel as an initial burst in the first 3 days followed by continuous release in the subsequent 2 weeks. The use of PLGA microspheres decreased the initial burst and extended dipyridamole release from 23 to 35 days with increasing MW of PLGA. The highest MW PLGA showed a lag time of 17 days before consistent drug release occurred. Mixing microspheres and ReGel with two different MW PLGA achieved a continuous release for 35 days with little initial burst. In vivo release of dipyridamole from microspheres/ReGel exhibited a comparable release pattern to that seen in vitro. This injectable platform is a promising technique for sustained perivascular delivery of antiproliferative drugs. © 2005 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 2006


📜 SIMILAR VOLUMES


Development, implantation, in vivo eluti
✍ Nathan R.F. Beeley; Jay M. Stewart; Ryotaro Tano; Laurie R. Lawin; Ralph A. Chap 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 381 KB 👁 2 views

## Abstract A biocompatible, sustained‐release subretinal drug‐delivery platform was developed to overcome the therapeutic accessibility limitations of current retinal disease treatments. The prototype implants were fabricated by coating nitinol, poly(methyl methacrylate) or chromic gut core filame

Sustained-release delivery systems of tr
✍ Doron Steinberg; Tamir Tal; Michael Friedman 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 988 KB

## Abstract Dental diseases are chronic infections caused by oral bacteria harboring the dental biofilm. Local sustained‐release delivery systems prolong the duration of a drug in the oral cavity, thus enhancing its therapeutic potential, while reducing its side effects. Triclosan is an agent that

Development of a sustained-release aspir
✍ Edward H. Wiseman; N. J. Federici 📂 Article 📅 1968 🏛 John Wiley and Sons 🌐 English ⚖ 406 KB

substituents should protect better and more effectively preclude interaction with a bioactive macromolecule. Rationalization t, because it is a combination of a and b, also is apparently disputed. The fact that the N,N-dialkylamides are as potent as the N-monoalkylamides could be rationalized as fo

Development of a polymeric patch impregn
✍ Anna Argemí; Jeffrey L. Ellis; Javier Saurina; David L. Tomasko 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 379 KB

This paper describes the preparation and characterization of transdermal patches impregnated with naproxen. A mixture of ethylene vinyl acetate and Eudragit R E100 (80:20, w/w) is used as a polymeric matrix to obtain a thin membrane to be impregnated. Drug impregnation is carried out under pressuriz